IDEAYA Biosciences Inc at Citi Global Technology Conference Transcript
Welcome, everyone. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. As long as I can remember, we always do a targeted oncology panel at our conference. So, this is the 2023 version of that panel. We have two terrific companies from IDEAYA, Paul Stone, CFO; from ORIC, Matt Panuwat, am I saying that correctly?
That's correct. Yeah.
Okay. Great. The Chief Business Officer; and from Syndax, Mike Metzger, the CEO. Thank you all so much for taking time out of the one-on-one scheduled to chat a little bit. Maybe we can just go down the line and just do a quick two to three minute high-level overview of what the company does, what are the key assets, maybe the key studies, and then we can get into a discussion about design considerations for targeted oncology drugs. So, you want to kick it off, Matt?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
